Leadless Pacemaker Feasible in Animal Models

Share this content:
Leadless Pacemaker Feasible in Animal Models
Leadless Pacemaker Feasible in Animal Models

MONDAY, May 15, 2017 (HealthDay News) -- A leadless anti-tachycardia pacemaker (LP) and subcutaneous implantable cardioverter defibrillator (S-ICD) are feasible in animal models, according to a study published online May 12 in JACC: Clinical Electrophysiology. The research was published to coincide with the annual meeting of the Heart Rhythm Society, held from May 10 to 13 in Chicago.

Fleur V.Y. Tjong, M.D., from the Academic Medical Center in Amsterdam, and colleagues evaluated the combined modular cardiac rhythm management therapy system of LP and S-ICD prototypes in three animal models (ovine, porcine, and canine) in acute and chronic experiments. The authors tested LP performance, S-ICD to LP communication, S-ICD and LP rhythm discrimination, and anti-tachycardia pacing (ATP) delivery triggered by the S-ICD.

LP and S-ICD were successfully implanted in 39 of 40 animals; 23 animals were followed for 90 days after implant. The researchers found that during 90 days of follow-up, LP performance was adequate and demonstrated appropriate single chamber pacemaker (VVI) behavior. In 99 percent of attempts, unidirectional communication between the S-ICD and LP was successful, resulting in 100 percent ATP delivery by the LP. During normal sinus rhythm, LP pacing, and ventricular tachycardia/ventricular fibrillation, adequate S-ICD sensing was observed.

"We demonstrated appropriate VVI functionality, successful wireless device-device communication, and ATP delivery by the LP," the authors write. "Clinical studies on safety and performance are needed."

Several authors disclosed financial ties to medical device companies, including Boston Scientific, which partially funded the study.

Abstract/Full Text (subscription or payment may be required)
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Cost-Effectiveness of PCSK9 Inhibitors Called Into Question

Cost-Effectiveness of PCSK9 Inhibitors Called Into Question

Researchers say price would have to be between $4,000 and $5,000 per year to be cost-effective

Vitamin B6, B12 Supplements May Up Risk of Lung Cancer in Men

Vitamin B6, B12 Supplements May Up Risk of ...

Increased odds only seemed to affect men or male smokers

Tablet Use Encourages Patients to Explore Diabetes Risk

Tablet Use Encourages Patients to Explore Diabetes Risk

Replacing magazines with tablets can help patients learn about diabetes risk, take preventive action

is free, fast, and customized just for you!

Already a member?

Sign In Now »